AI pipeline control and new cure approvals both accelerate

Today’s cure pipeline remains busy at scale: 21,156 global active cure-related trials, with fresh signals and research continuing to stack (57 new Wire signals, 18 new Cure research in the last 24h). On the approval side, China’s NMPA accepted the marketing file for HRS-7535, and the US FDA cleared AstraZeneca’s Etcamah in combination for HR-positive, HER2-negative breast cancer—two concrete steps where biology meets regulation. In parallel, the intelligence shows the AI phase transition tightening control and capability: Nvidia’s planned acquisition of Hugging Face signals a shift in distribution gatekeeping toward vendor-controlled pipelines, while new GPT-6 Astra claims point toward upgraded cognitive labor for coding/reasoning. The stakes are straightforward: faster discovery and translation benefit humanity, but a more centralized AI distribution system can also reshape access and incentives—so the most important work now is to keep alignment, openness of scientific workflows, and medical evidence moving at pace. The window is still open.